AR129166A1 - Bacteriófagos con actividad lítica contra mycobacterium - Google Patents

Bacteriófagos con actividad lítica contra mycobacterium

Info

Publication number
AR129166A1
AR129166A1 ARP230101025A ARP230101025A AR129166A1 AR 129166 A1 AR129166 A1 AR 129166A1 AR P230101025 A ARP230101025 A AR P230101025A AR P230101025 A ARP230101025 A AR P230101025A AR 129166 A1 AR129166 A1 AR 129166A1
Authority
AR
Argentina
Prior art keywords
activity against
bacteriophage
against mycobacterium
bacteriophages
mycobacterium
Prior art date
Application number
ARP230101025A
Other languages
English (en)
Spanish (es)
Inventor
Hiroki Ando
Hideaki Matsuoka
Koji Matsukawa
Yutaro Ono
Shoichi MITSUNAKA
Original Assignee
Astellas Pharma Inc
National Univ Corporation Tokai National Higher Education And Research System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, National Univ Corporation Tokai National Higher Education And Research System filed Critical Astellas Pharma Inc
Publication of AR129166A1 publication Critical patent/AR129166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP230101025A 2022-04-28 2023-04-27 Bacteriófagos con actividad lítica contra mycobacterium AR129166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022075078 2022-04-28

Publications (1)

Publication Number Publication Date
AR129166A1 true AR129166A1 (es) 2024-07-24

Family

ID=88518795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101025A AR129166A1 (es) 2022-04-28 2023-04-27 Bacteriófagos con actividad lítica contra mycobacterium

Country Status (5)

Country Link
EP (1) EP4516898A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023210732A1 (cg-RX-API-DMAC7.html)
AR (1) AR129166A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400783A (cg-RX-API-DMAC7.html)
WO (1) WO2023210732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4745231A1 (en) * 2023-07-14 2026-05-20 Arrowsmith Inc. MODIFIED BACTERIOPHAGE
CN122060690A (zh) * 2026-04-01 2026-05-19 深圳市百泽诺科生物技术有限公司 一种分枝杆菌噬菌体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010043924A1 (en) * 1994-04-05 2001-11-22 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
EP2579883A1 (en) * 2010-06-08 2013-04-17 Leah Robert Bacteriophages for use against bacterial infections
EP3358015A1 (en) * 2017-02-03 2018-08-08 Eligo Bioscience Optimized vector for delivery in microbial populations
US11066691B1 (en) * 2018-09-14 2021-07-20 National Technology & Engineering Solutions Of Sandia, Llc Therapeutic phages and methods thereof
US12576118B2 (en) * 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
WO2021092362A1 (en) * 2019-11-07 2021-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections

Also Published As

Publication number Publication date
TW202400783A (zh) 2024-01-01
EP4516898A4 (en) 2026-05-06
EP4516898A1 (en) 2025-03-05
WO2023210732A1 (ja) 2023-11-02
JPWO2023210732A1 (cg-RX-API-DMAC7.html) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112017013233A2 (pt) bacteriófago clo-pep-1 de clostridium perfringens inovador e uso do mesmo para a inibição de proliferação de clostridium perfringens
CO2017006495A2 (es) Bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
Pottumarthy et al. Nocardia veterana, a new emerging pathogen
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
BR112018015211A2 (pt) indicadores biológicos
MX393266B (es) Composiciónpara usarse en terapia de microbiota
Meyer et al. In vivo efficacy of apramycin in murine infection models
BR112022003129A2 (pt) Dispositivos e métodos para a detecção de microrganismos usando bacteriófago indicador recombinante deficiente em reprodução
MX2025000629A (es) Cepas de lactobacillus salivarius y usos de las mismas
BR112022026001A2 (pt) Microrganismo com atividade intensificada de 3-metil-2-oxobutanoato hidroximetiltransferase e usos do mesmo
AR075013A1 (es) Composicion farmaceutica para proteger a un animal contra un trastorno causado por una infeccion con una bacteria que pertenece al grupo de acttinomicetes nocardioformes. uso. metodo.
JPWO2023210732A5 (cg-RX-API-DMAC7.html)
Kalorey et al. PCR analysis of Pasteurella multocida isolates from an outbreak of pasteurellosis in Indian pigs
WO2020099478A3 (en) Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
CO2020010533A2 (es) Novedoso bacteriófago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg
Gomez et al. Detection of phospholipase C in nontuberculous mycobacteria and its possible role in hemolytic activity
MX2021015900A (es) Metodos para producir bacteriofagos mutantes para la deteccion de listeria.
AR128262A1 (es) Enzima fosfolipasa c mutada y procedimiento de desgomado enzimático
Sridhar et al. First report of human infection by Agromyces mediolanus, a Gram-positive organism found in soil
WO2020099482A3 (en) Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
Verona et al. Bacteremia and sepsis by Arcanobacterium haemolyticum in a young immunocompetent patient
WO2025019632A3 (en) Novel rufomycin analogs as clpc1 protease modulators having activity against mycobacterium tuberculosis
WO2019063792A3 (en) OLIGONUCLEOTIDE INHIBITING CHOP EXPRESSION
AR025410A1 (es) Metodo para preparar una bacteria s. thermophilus resistente al ataque de por lo menos un bacteriofago

Legal Events

Date Code Title Description
FB Suspension of granting procedure